Apollon Formularies is a London, England and Jamaican based publicly traded (AQUS:APOL), international medical cannabis pharmaceutical company specialising in cutting edge research and treatment of patients with cancer and chronic pain. Apollon is federally legal, licensed by the Cannabis Licensing Authority (CLA) in Jamaica, holds a suite of CLA licences which allow the company to work with full spectrum oils inclusive of high levels of THC. Apollon medical cannabis formulations are currently available by prescription to any licensed Jamaican doctor for their patients and for export via licensed partners to any jurisdiction allowing legal import.
To become the premier global medical cannabis company legally licensed to develop successful personalised clinical treatment utilizing artificial intelligence on clinical trial patient data.
Apollon’s Research & Development Licence allows drug discovery using THC and other cannabinoids. This allows Apollon to be the rare European listed company conducting medically supervised trials using THC to develop new therapeutics.
It aims to create a globally recognised brand synonymous with quality, consistent potency, and successful patient outcomes on a range of products for a variety of conditions within the medical cannabis space.
Apollon Formularies will, through its subsidiary Apollon Formularies Jamaica Ltd (a fully licensed full spectrum medical cannabis company), develop, market, distribute and sell full spectrum (inclusive of THC) products in the legal hemp and medical cannabis industry. It is currently producing pharmaceutical, nutraceutical and other medical cannabis related products. Apollon Formularies was established to advance the current significant commercial opportunities in the legal medical cannabis markets globally.
Use of artificial intelligence
Apollon uses the latest state-of-the-art artificial intelligence techniques to optimize strain genetics for medical cannabis formulation development and to analyse patient genomic data to identify new potential biomarkers to triage patients into the correct treatment protocols.
Processing & extraction
Apollon’s CLA licensed Processing Laboratory is based in Negril, Jamaica. This state-of-the-art medical cannabis processing facility produces medical quality full spectrum medical cannabis oil (inclusive of THC). Apollon recently won the prestigious Jack Herer Cup 1st Place for Best Oil (solvent) which was produced in our Negril laboratory.
Medically supervised treatments
The company is currently opening the Apollon International Cancer Institute in Kingston, Jamaica to add to our patient treatment and clinical trial capacity currently in Negril, Jamaica.
Apollon has a full team of licensed Jamaican medical doctors specialising in oncology, palliative care, chronic pain, neurosurgery, surgery and general wellness with additional expertise in treating patients with Apollon medical cannabis products which are available in Jamaica by prescription only.
Apollon Formularies Jamaica is licensed to operate at the Federal level in Jamaica through the following licences:
- Human Research & Development (R&D)
- Cannabis Cultivation (R&D)
- Retail Dispensary (Therapeutic)
Together these licences create a vertically integrated full spectrum (inclusive of THC) medical cannabis company both in Jamaica and to the international market via legal export from Jamaica to jurisdictions where the law allows import of medical cannabis products.
Apollon’s Timeline of Global Accomplishments
- Corporate milestones
- Intellectual achievements
- Awards & accolades
Apollon Formularies created by Dr. Stephen Barnhill and his family in order to help cancer patients globally with medical cannabis as it helped his mother who suffered with pancreatic cancer.
Completes Artificial Intelligence (AI) analysis for best strains to treat cancer and other conditions.
Invited to present artificial intelligence cannabis strain results at the medical school at The University of the West Indies.
Expands operations to Jamaica.
Wins 1st place at the Jamaican International HighTimes Cannabis Cup for best Indica strain used to treat cancer patients.
Signs Memorandum of Understanding (MOU) with the University of the West Indies to perform fundamental, academic and medical patient research and allowed production and sales of medical cannabis for cancer patients.
Apollon Negril Facility opens for cancer patients using Apollon medical cannabis.
Apollon Receives Cannabis Licence Authority (CLA) Conditional Approval for cultivation, processing, research and development for manufacturing medical cannabis products and treating cancer patients.
Approved by CLA for full licence for Research and Development (Experimental).
Approved by CLA for full licences for Retail (Theraputic) and Processing (Tier 2).
Establishes Pharmaceutical Processing Labratory.
Wins prestigious Jack Herer Cup 1st place for best medical cannabis oil (solvent). Same Apollon oil used to treat cancer patients.
Apollon Negril Facility wins 1st in the world for medical cannabis health and wellness resort selected by Edibles magazine.
Apollon medical proprietary cannabis treatment formulations tested by 3rd party independent laboratory testing at BIOENSIS with results expected in early 2021.
Expands to Europe and becomes one of the first publicly listed medical cannabis companies on the Aquis exchange in London licenced to have high THC prescription medical products (AQUS:APOL).
Joint testing by BIOENSIS has revealed combined formulations with Aion Therapeutics Inc. are effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
Opens the Apollon International Cancer Institute for Complementary and Alternative Medicine (CAM), in Jamaica with medical cannabis treatments available by physician prescription.
Apollon’s medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures in third party independent laboratory testing by BIOENSIS.